Treatment of Hyperkalemia in Patients with Kidney Failure

Classification and Management

The European Society of Cardiology recommends a tiered approach to treating hyperkalemia in kidney failure, with immediate stabilization of cardiac membranes, intracellular potassium shifting, and potassium removal from the body through dialysis or potassium binders in severe cases 1, 2
Hyperkalemia can be classified into three categories: mild (>5.0 to <5.5 mEq/L), moderate (5.5 to 6.0 mEq/L), and severe (>6.0 mEq/L) 3

The European Heart Journal recommends administering IV calcium chloride or calcium gluconate to stabilize cardiac membranes in severe hyperkalemia or ECG changes 1, 2
Insulin (10 units IV) with glucose (50 ml of 50% solution) can be administered to shift potassium intracellularly, with a temporary benefit of 1-4 hours 1
Sodium bicarbonate IV can be considered if metabolic acidosis is present, with the strength of evidence being moderate 1, 2

The European Heart Journal recommends identifying and discontinuing medications that contribute to hyperkalemia, such as potassium-sparing diuretics, NSAIDs, and beta-blockers 1, 3
Restricting potassium-rich foods and supplements, and avoiding salt substitutes containing potassium, can help prevent hyperkalemia 3
Individualizing the frequency of potassium monitoring based on CKD stage, medications, and previous hyperkalemia episodes is crucial, with more frequent monitoring in advanced CKD (stages 4-5) 4, 6

Patients with kidney failure may tolerate slightly higher potassium levels (optimal range 3.3-5.5 mEq/L in CKD stages 4-5) compared to those with normal kidney function (optimal range 3.5-5.0 mEq/L) 6, 7
Newer potassium binders, such as patiromer sorbitex calcium (PSC) or sodium zirconium cyclosilicate (SZC), may allow continuation of beneficial RAAS inhibitors in patients with heart failure, diabetes, or hypertension with kidney disease, with a strength of evidence being high 4, 8